Hologic, Inc. (NASDAQ:HOLX) Receives Health Canada Authorization to Market SculpSure® Laser


Hologic, Inc. (NASDAQ:HOLX) has announced that it has been issued with a medical device license by Health Canada that will allow the company to market SculpSure, Cynosure’s advanced non-invasive body contouring product. SculpSure is used in the treatment of inner, outer and back thighs as well as submental area.

As opposed to other technologies, SculpSure uses laser to increase the temperature of fats in the body so as to disrupt and destroy fats cells that are beneath the skin. The whole process is aimed at helping the patient attain a slimmer and natural-looking appearance. The body then gets rid of the fat cells naturally.

It is important to note that SculpSure laser body treatments are mainly recommended for patients that have a body mass index that is 30 or below. SculpSure laser submental treatments are very effective on patient that have body mass index of up to 43. This is a big advantage over its main competitor cryolipolysis, which has been approved for treatment of patients that have a body mass index of 30 in the submental area.

In a statement, Hologic President in charge of the Cynosure division Kevin Thornal said that the license is a clear indication of the company’s commitment to research as well as working hard to meet the needs of millions of patients. He added that being the leading company in medical aesthetics, they are always working hard to secure new indications which offer exceptional efficacy.

The authorization will be for outer, inner and back thighs and will not need any update to devices purchased previously. However, the submental treatment will need qualified practitioners to do an upgrade of their SculpSure device and but a much simple laser attachment with the allowance for the applicator to fit smoothly onto the area being treated. The sales team will start distribution immediately to interested practitioners.

Cynosure is one of the leaders in the development and manufacturing of several medical aesthetics systems and technologies. The company boasts of an extensive portfolio of over 20 products in major categories including skin revitalization, body contouring, women’s health and hair removal.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.